Support AlterNet
Do you value the information you're getting from AlterNet? Please show your support with a tax-deductible donation.
Feedback
Tell us how we're doing.
The $200 Billion Colossus
Corporate Accountability and WorkPlace:
Today's Economic Crisis in Historical Perspective
Democracy and Elections:
More Unfinished 2008 Election Business: Verifiable Vote Counts
Steven Rosenfeld
DrugReporter:
A New Approach to Drugs Would Save New York Hundreds of Millions of Dollars
Gabriel Sayegh
Election 2008:
Franken Lawyer: "We Are Going To Win"
Sam Stein
Environment:
Forget the Polar Bears -- The Climate Crisis Is About All of Us
George Monbiot
ForeignPolicy:
What Venezuela's Regional Elections Really Mean
Olivia Burlingame Goumbri
Health and Wellness:
Obama's Health Care Reform Plan Is Based on the Clintons' Failed 1990s Model
Marie Cocco
Hurricane Katrina:
From the Bayou to Baghdad: Mission Not Accomplished
Amy Goodman
Immigration:
Immigration Reform After Bush: Let's Put an End to Punitive Policies
Roberto Lovato
Media and Technology:
Born Digital: Understanding the First Generation of Digital Natives
Doron Taussig
Movie Mix:
Love Bites: What Sexy Vampires Tell Us About Our Culture
Sarah Seltzer
Reproductive Justice and Gender:
The Hymen Mystique
Carole Roye
Rights and Liberties:
Ban the Cluster Bomb
Brian Cook
Sex and Relationships:
Sex Ed for Seniors
Sue Katz
War on Iraq:
The Dilemma of Foreign Prisoners in Iraq
Ma'ad Fayad
Water:
Corporate Water Abusers Should Not Be Trusted As Stewards of the World's Water
Wenonah Hauter
The following is taken from Chapter 1 of The Truth About Drug Companies by Marcia Angell, published by Random House.
What does the eight-hundred-pound gorilla do?
Anything it wants to.
What's true of the eight-hundred-pound gorilla is true of the colossus that is the pharmaceutical industry. It is used to doing pretty much what it wants to do. The watershed year was 1980. Before then, it was a good business, but afterward, it was a stupendous one. From 1960 to 1980, prescription drug sales were fairly static as a percent of U.S. gross domestic product, but from 1980 to 2000, they tripled. They now stand at more than $200 billion a year. Furthermore, since the early 1980s, this industry has consistently ranked as the most profitable in the United Statesby a long shot. (Only in 2003 did it fall from that position to rank third among the forty-seven industries listed in the Fortune 500.) Of the many events that contributed to their sudden great and good fortune, none had to do with the quality of the drugs the companies were selling.
In this chapter I'll give you an overview of the pharmaceutical industry – its meteoric rise and the recent, early signs of either a coming fall or an overhaul. I will not go into much detail here; I'll leave that to later chapters. What I want to do now is provide a quick look at what's under this rock when it's lifted. It's not a pretty sight.
Before I begin, a few words about the facts and figures I will use throughout the book. In most cases, I use data from the year 2001, because it is the most recent year for which information is reasonably complete for all the aspects of the industry I will consider. If I stick with one year, it will make it easier to see the whole picture. But for some important facts, I will use figures from 2002 and, whenever possible, 2003. In all cases, I will make it clear what year I am talking about.
I also need to explain what I mean when I say this is a $200 billion industry. According to government sources, that is roughly how much Americans spent on prescription drugs in 2002. That figure refers to direct consumer purchases at drugstores and mail order pharmacies (whether paid for out of pocket or not), and it includes the nearly 25 percent markup for wholesalers, pharmacists, and other middlemen and retailers. But it does not include the large amounts spent for drugs administered in hospitals, nursing homes, or doctors offices (as is the case for many cancer drugs). In most analyses, they are allocated to costs for those facilities.
Drug company revenues (or sales) are a little different, at least as they are reported in summaries of corporate annual reports. They usually refer to a company's worldwide sales, including those to health facilities. But they do not include the revenues of middlemen and retailers.
Perhaps the most quoted source of statistics on the pharmaceutical industry, IMS Health, estimated total worldwide sales for prescription drugs to be about $400 billion in 2002. About half were in the United States. So the $200 billion colossus is really a $400 billion megacolossus, but my focus in this book will be mainly on how the drug companies operate in the United States.
You should understand, however, that it is virtually impossible to be precise about most of these figures. Before drugs reach consumers, they pass through many hands and are paid for in exceedingly complicated, often hidden, ways. It is easy to compare apples and oranges without knowing it. You need to ask, for example, whether a number refers just to prescription drugs or includes over-the-counter drugs and other consumer products made by drug companies; whether it includes revenues for middlemen and retailers or not; whether it refers just to outpatient consumer purchases or also to health facility purchases; and whether it includes mail order purchases.
Let the Good Times Roll
The election of Ronald Reagan in 1980 was perhaps the most fundamental element in the rapid rise of big pharma – the collective name for the largest drug companies. With the Reagan administration came a strong pro-business shift not only in government policies but in society at large. And with the shift, the public attitude toward great wealth changed. Before then, there was something faintly disreputable about really big fortunes. You could choose to do well or you could choose to do good, but most people who had any choice in the matter thought it difficult to do both. That belief was particularly strong among scientists and other intellectuals. They could choose to live a comfortable but not luxurious life in academia, hoping to do exciting cutting-edge research, or they could "sell out" to industry and do less important but more remunerative work. Starting in the Reagan years and continuing through the 1990s, Americans changed their tune. It became not only reputable to be wealthy, but something close to virtuous. There were "winners" and there were "losers," and the winners were rich and deserved to be. The gap between the rich and poor, which had been narrowing since World War II, suddenly began to widen again, until today it is a yawning chasm.
The pharmaceutical industry and its CEOs quickly joined the ranks of the winners as a result of a number of business-friendly government actions. I won't enumerate all of them, but two are especially important. Beginning in 1980, Congress enacted a series of laws designed to speed the translation of tax-supported basic research into useful new products – a process sometimes referred to as "technology transfer." The goal was also to improve the position of American-owned high-tech businesses in world markets. The most important of these laws is known as the Bayh-Dole Act, after its chief sponsors, Senator Birch Bayh (D-Ind.) and Senator Robert Dole (R-Kans.). Bayh-Dole enabled universities and small businesses to patent discoveries emanating from research sponsored by the National Institutes of Health (NIH), the major distributor of tax dollars for medical research, and then to grant exclusive licenses to drug companies. Until then, taxpayer-financed discoveries were in the public domain, available to any company that wanted to use them. But now universities, where most NIH-sponsored work is carried out, can patent and license their discoveries, and charge royalties. Similar legislation permitted the NIH itself to enter into deals with drug companies that would directly transfer NIH discoveries to industry.
From the Book: THE TRUTH ABOUT THE DRUG COMPANIES by Marcia Angell, M.D. Copyright (c) 2004 by Marcia Angell Published by arrangement with Random House, an imprint of The Random House Publishing Group, a division of Random House, Inc.
Liked this story? Get top stories in your inbox each week from AlterNet! Sign up now »
| More Excerpts: | ||
|
Why the Democrats Are Winning Back the South Election 2008: The more Democrats focus on economic fairness in the South, the better their chance to shut down the right's culture wars. By Bob Moser, Texas Observer. November 5, 2008. |
The Plot Against Liberal America Democracy and Elections: Conservatives don't want to debate, they want to destroy their opposition. By Thomas Frank, The New Statesman. August 18, 2008. |
How Washington's Right-Wing Wrecking Crew Robbed Us Blind Democracy and Elections: Conservatives have turned a vast government built for our protection into a device for exploiting us. By Thomas Frank, Tomdispatch.com. August 6, 2008. |